NCT02730351 - Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2016

Primary Completion Date

February 3, 2017

Study Completion Date

February 3, 2017

Conditions

Asthma

Interventions

DRUG

Fluticasone furoate/ Vilanterol 100 mcg/25 mcg

FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening

DRUG

Fluticasone propionate 250 mcg

FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening

DRUG

Placebo via ELLIPTA inhaler

Placebo will be administered via ELLIPTA inhaler once daily in the evening

DRUG

Placebo via DISKUS / ACCUHALER

Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening

Trial Locations (16)

21236

GSK Investigational Site, Baltimore

27607

GSK Investigational Site, Raleigh

29118

GSK Investigational Site, Orangeburg

29414

GSK Investigational Site, Charleston

31406

GSK Investigational Site, Savannah

32308

GSK Investigational Site, Tallahassee

79903

GSK Investigational Site, El Paso

80230

GSK Investigational Site, Denver

90025

GSK Investigational Site, Los Angeles

92123

GSK Investigational Site, San Diego

92647

GSK Investigational Site, Huntington Beach

92648

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford

T8H 0N2

GSK Investigational Site, Sherwood Park

L4W 1A4

GSK Investigational Site, Mississauga

L5A 3V4

GSK Investigational Site, Mississauga